cultivate(MD) - cultivate(MD)

Shoulder Innovations a cultivate(MD) portfolio company

Shoulder Innovations Reports First Quarter 2026 Financial Results and Raises Full Year Outlook

Press Release / May 13, 2026

Generates First Quarter Net Revenue Growth of 65% Year-Over-Year Shoulder Innovations, Inc. (NYSE: SI), a cultivate(MD) portfolio company reported financial results for the first quarter ended March 31, 2026. First Quarter Financial Highlights Recent Business Highlights “We are very pleased with our first quarter performance, which reflects accelerating revenue growth and intensifying commercial momentum across […]

Shoulder Innovations Reports First Quarter 2026 Financial Results and Raises Full Year Outlook Read More »

cultivate(MD) Focus Fund Announces Initial Capital Deployments

Press Release / May 11, 2026

The Focus Fund is cultivate(MD)’s fifth vehicle: a 2031-horizon strategy to identify, support, and exit best-in-class early-stage medical device companies. GRAND RAPIDS, Mich., May 11, 2026 — cultivate(MD), a leading medical device venture capital company, announced that its Focus Fund has deployed capital across four portfolio companies over the past month. THIS PRESS RELEASE IS

cultivate(MD) Focus Fund Announces Initial Capital Deployments Read More »

Capitan Orthopedics a cultivate(MD) portfolio company

Capitan Orthopedics, Inc. Announces Breakthrough Device Designation for its SupraSpacer™ Implant

News / May 5, 2026

cultivate(MD) portfolio company Capitan Orthopedics, Inc. announced that it has been granted Breakthrough Device Designation from the U.S. Food & Drug Administration (FDA) for its SupraSpacer™ implant. “I am excited to announce that Capitan Orthopedics, Inc. has received Breakthrough Device Designation for its SupraSpacer™ implant technology. This is yet another milestone achievement for our team

Capitan Orthopedics, Inc. Announces Breakthrough Device Designation for its SupraSpacer™ Implant Read More »

Shoulder Innovations is a cultivate(MD) portfolio company launching I-135RFX humeral stem

Shoulder Innovations Initiates Full Commercial Launch of the InSet® I-135RFX Humeral Stem

News / May 1, 2026

cultivate(MD) portfolio company Shoulder Innovations, Inc., (NYSE: SI) announced full commercial launch of the InSet® I-135RFX Humeral Stem. The commencement of full launch follows a successful limited market release and receipt of additional FDA 510(k) clearance for an expanded set of fracture indications, enabling the InSet™ I-135RFX to now be utilized in all primary, revision,

Shoulder Innovations Initiates Full Commercial Launch of the InSet® I-135RFX Humeral Stem Read More »

Strados Labs Acquires Clinical Trial Business of NuvoAir

News / April 16, 2026

cultivate(MD) portfolio company Strados Labs, the respiratory endpoint intelligence company, announced the acquisition of NuvoAir Clinical Trials from NuvoAir Inc. The transaction, which closed in March 2026, expands Strados’ suite of solutions to include remote and in-clinic spirometry, FeNO measurement, and electronic clinical outcome assessment (eCOA) — complementing its existing technologies for cough monitoring and

Strados Labs Acquires Clinical Trial Business of NuvoAir Read More »

Prana Surgical Announces the Prana System™ Receives FDA Clearance

Press Release / April 2, 2026

Image-guided platform enables minimally invasive, tissue-sparing excision. HOUSTON, April 2, 2026 /PRNewswire-PRWeb/ — Prana Surgical, a Houston-based medical device company, announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for the Prana System™, an electrosurgical device indicated to remove tissue and control bleeding. The Prana System is a sterile, single-use electrosurgical

Prana Surgical Announces the Prana System™ Receives FDA Clearance Read More »

Author name: cultivate(MD)